Invention Grant
US08669100B2 DNA expression constructs encoding the Leishmania infantum antigens thiol-specific antioxidant protein and kinetoplastid membrane protein
有权
编码利什曼原虫婴幼儿抗原硫蛋白特异性抗氧化蛋白和动粒细胞膜蛋白的DNA表达构建体
- Patent Title: DNA expression constructs encoding the Leishmania infantum antigens thiol-specific antioxidant protein and kinetoplastid membrane protein
- Patent Title (中): 编码利什曼原虫婴幼儿抗原硫蛋白特异性抗氧化蛋白和动粒细胞膜蛋白的DNA表达构建体
-
Application No.: US12841713Application Date: 2010-07-22
-
Publication No.: US08669100B2Publication Date: 2014-03-11
- Inventor: Burghardt Wittig , Laura Fuertes-López , Marcos Timón-Jiménez
- Applicant: Burghardt Wittig , Laura Fuertes-López , Marcos Timón-Jiménez
- Applicant Address: DE Berlin
- Assignee: Mologen AG
- Current Assignee: Mologen AG
- Current Assignee Address: DE Berlin
- Agency: 24IP Law Group
- Agent Timothy R. DeWitt
- Priority: EP03090368 20031024
- Main IPC: C12N15/00
- IPC: C12N15/00 ; A61K48/00
Abstract:
The invention relates to using a combination of DNA-expression constructs for producing a drug for immunization against leishmania infections and a corresponding vaccine. The DNA-expression construct is also disclosed. According to said invention the immunogene P36 LACK is used in combination with a leishmania infantum thiol-specific antioxidant protein gene (TSA), leishmania infantum kinetoplastid membrane protein 11 (KMP-11) and with a leishmania infantum GP63 antigen for producing an immune response. Plasmides, preferably minimalist immunologically defined gene-expression constructs (MIDGE) can be used in the form of the DNA-expression construct. The inventive DNA-expression construct makes it possible to produce a vaccine for treating leishmania infectious diseases and is used in the form of a component of said vaccine.
Public/Granted literature
- US20110223189A1 AGENT FOR TREATING LEISHMANIA INFECTIONS Public/Granted day:2011-09-15
Information query
IPC分类:
